Navigation Links
ENDEAVOR III Trial Reports Key Findings on New-generation Stent

New data reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 912, 2007, in Orlando, FL, will offer clues to the fate of a new-generation drug-eluting stent that is vying for a place in the treatment of coronary artery disease.

The Endeavor III trial randomly assigned 436 patients treated at 30 medical centers in the United States to treatment with the investigational Endeavor stent (Medtronic, Minneapolis) or the Cypher stent (Cordis Johnson & Johnson, Miami Lakes, FL). The Endeavor stent is coated with zotarolimus, a medication that, like the Cyphers sirolimus coating, reduces renarrowing of the artery by preventing the growth of scar tissue inside the stent.

Initial data showed that procedural success was higher with the new Endeavor stent, which is more flexible and is considered easier to implant than the Cypher stent. However, at 8 months, the Endeavor stent fell short in angiographic studies, showing significantly greater scar tissue growth, or late loss, in the inner diameter of the artery as compared to the Cypher stent. At 12 months, clinical outcomes were equivalent with the two stents: The combined rates of death, heart attack, and repeat procedures were 8.2 percent in both groups of patients.

At the Orlando SCAI meeting, Martin Leon, M.D., FSCAI, a professor of medicine and associate director of the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York City, will report 2-year clinical outcomes from the Endeavor III trial.

"Long-term follow-up will further clarify not only safety with the zotarolimus-eluting stent but also whether early angiographic disparities translate into differences in late clinical restenosis," he said.

The Endeavor III trial is 1 of 5 studies gathering the data necessary for market approval of the new stent by the Food and Drug Administration.


'"/>




Page: 1

Related medicine news :

1. Results Of Human Trials Of Hungarian Bird-Flu Vaccine Expected Today
2. Vaccine For Dengue Fever On Trial In Asia-Pacific
3. DNA Vaccine Trials Against HIV Virus In Sweden Nurture Hope
4. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
5. Sex, Race Influence Lung Cancer Trial Participation
6. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
7. Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection
8. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
9. China Begins Human Trials For HIV/AIDS Drug
10. Patients Should Be Entitled to "Humane Compensation" if Drug Trials Go Wrong
11. HIV/AIDS Vaccine Trial To Be Initiated Soon
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ENDEAVOR III Trial Reports Key Findings New generation Stent

(Date:8/3/2015)... , ... August 03, 2015 , ... ... and development solutions for drugs, biologics and consumer health products, today welcomed the ... for review OPKO’s New Drug Application for a new treatment for chronic kidney ...
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
(Date:8/3/2015)... ... 03, 2015 , ... A July 13 article from The Daily Mail titled ... Natural Painkiller That Can Last 'For Five Weeks'" discusses the use of stem ... study showed that harvesting stem cell-rich bone marrow from the hip, known as bone ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... today that Joe Williams has joined its growing California employee benefits division. ... service model to his clients. Mr. Williams will be joining the newly integrated ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... A new study has dismissed any association between consumption of ... association between total calcium intake//, and consequent changes in body ... intake of calcium. ,More than 19,000 men between ... a 12-year period. All of the study participants consumed a ...
... health benefits. Now, teens, who want that dream weight, can ... obesity at bay, according to a new study. Researchers at ... combined yoga with breathing exercises certainly helped knock off the ... boys participated in a study. They were divided into two ...
... appear to have scaled up following the improvement in ... flu outbreak abated.// , ,According to an official ... been some improvement in the movement of these commodities ... in the last four days. Poultry consumption too has ...
... Information (CIHI) said that despite the government investing a ... of waiting time. // Glenda Yeates, president of the ... and high-priority procedures has increased dramatically. ,But ... much. Statistics show that the number of angioplasties and ...
... study claims that calcium intake was not associated with weight ... published in the American Journal of Clinical Nutrition. ... enrolled in the Health Professionals Follow-up Study were taken as ... between total calcium intake from diet and supplements and changes ...
... eastern Sarawak state of Malaysia is causing concern among Malaysian ... all schools in the area to prevent the disease from ... causes the disease, has so far affected more than a ... peninsular Malaysia, the health ministry will take a clear line ...
Cached Medicine News:
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, 2015 ... OFF HOLD -- FN Media Group LLC, PIV757417 ... Partnerships Focus on Developing Orphan Drug Products & ... is now OFF HOLD. Distribution time: 3 Aug ... development agreements between biotech companies, military surgical research ...
(Date:8/3/2015)... FRANCISCO, Calif. , Aug. 3, 2015 /PRNewswire/ ... the treatment of cancer, today announced the promotion ... Debanjan Ray , who previously served ... management, has been promoted to senior vice president ... CytomX, Mr. Ray held positions as the vice ...
(Date:8/3/2015)... OSAKA, Japan and FLORHAM PARK, ... today announced that once-daily naldemedine met its primary and ... for the treatment of opioid-induced constipation (OIC) in adult ... oral, peripherally acting mu-opioid receptor antagonist (PAMORA). This is ... its primary and key secondary endpoints. Study ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... The ESR-100 is an automated 100-position ESR ... 50 samples daily. The instrument accurately and ... in 1.2ml or 2.0ml ESR-Vacuum Tubes. Results ... Westergren Method) and are available in 30 ...
The CA-500 series quickly and accurately measures up to 5 coagulation parameters. It is the analyzer of choice for low to mid volume laboratories, or as a backup to larger coagulation analyzers....
... Qwik-Let® Premier is our top-of-the-line ... the attributes of the Qwik-Let® ... patented Lan-X feature. The Lan-X ... and protection in the removal ...
... The new Finnpipette Focus from Thermo ... with uncompromising performance. Advanced features such ... .01ul fine volume adjustment on microvolumes help ... in single channel pipettes. The new interchangeable ...
Medicine Products: